Company Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases.
The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
The company was incorporated in 2012 and is based in San Diego, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Apr 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Dr. Jeffrey L. Stein Ph.D. |
Contact Details
Address: 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 United States | |
| Phone | 858-752-6170 |
| Website | cidara.com |
Stock Details
| Ticker Symbol | CDTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001610618 |
| CUSIP Number | 171757107 |
| ISIN Number | US1717571079 |
| Employer ID | 46-1537286 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey L. Stein Ph.D. | President, Chief Executive Officer and Executive Director |
| Dr. Preetam Shah M.B.A., Ph.D. | Chief Financial Officer, Chief Business Officer and Principal Accounting Officer |
| Dr. Taylor Sandison | Chief Medical Officer |
| Dr. Kevin M. Forrest Ph.D. | Founder and Chief Strategy Officer |
| Shane M. Ward | Chief Operating Officer and Chief Legal Officer |
| Allison Lewis CCP, SPHR | Senior Vice President of People and Culture |
| Dr. Leslie Tari Ph.D. | Chief Scientific Officer |
| Laura A. Navalta | Senior Vice President of Clinical Operations |
| Dr. Nicole Davarpanah J.D., M.D. | Senior Vice President of Translational Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 18, 2024 | 8-K | Current Report |
| Jun 3, 2024 | ARS | Filing |
| Jun 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 3, 2024 | DEF 14A | Other definitive proxy statements |
| May 23, 2024 | PRE 14A | Other preliminary proxy statements |
| May 20, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | D | Notice of Exempt Offering of Securities |